Owned by the Association for International Promotion & Study in Tumors (APSIT)
Articles
Page 12 of 77
-
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:342
-
Correction: Long noncoding RNA MAPKAPK5-AS1 promotes colorectal cancer progression by cis-regulating the nearby gene MK5 and acting as a let-7f-1-3p sponge
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:341 -
EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax
Acute myeloid leukemia (AML) is an aggressive hematological cancer resulting from uncontrolled proliferation of differentiation-blocked myeloid cells. Seventy percent of AML patients are currently not cured wi...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:340 -
Correction: Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:339 -
The A-to-I editing of KPC1 promotes intrahepatic cholangiocarcinoma by attenuating proteasomal processing of NF-κB1 p105 to p50
Aberrant RNA editing of adenosine-to-inosine (A-to-I) has been linked to multiple human cancers, but its role in intrahepatic cholangiocarcinoma (iCCA) remains unknown. We conducted an exome-wide investigation...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:338 -
MNX1-AS1, a c-Myc induced lncRNA, promotes the Warburg effect by regulating PKM2 nuclear translocation
Altered glycolysis is the most fundamental metabolic change associated with the Warburg effect. Some glycolytic enzymes such as PKM2, the dominant pyruvate kinase in cancer cells, have been shown to engage in ...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:337 -
TRIM56 promotes malignant progression of glioblastoma by stabilizing cIAP1 protein
The tripartite motif (TRIM) family of proteins plays a key role in the developmental growth and therapeutic resistance of many tumors. However, the regulatory mechanisms and biological functions of TRIM protei...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:336 -
LncRNA CEBPA-DT promotes liver cancer metastasis through DDR2/β-catenin activation via interacting with hnRNPC
Hepatocellular carcinoma (HCC) is the world’s third leading cause of cancer-related death; due to the fast growth and high prevalence of tumor recurrence, the prognosis of HCC patients remains dismal. Long non...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:335 -
A functional loop between YTH domain family protein YTHDF3 mediated m6A modification and phosphofructokinase PFKL in glycolysis of hepatocellular carcinoma
N6-methyladenosine (m6A) modification plays a critical role in progression of hepatocellular carcinoma (HCC), and aerobic glycolysis is a hallmark of cancer including HCC. However, the role of YTHDF3, one member ...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:334 -
Complexity of progranulin mechanisms of action in mesothelioma
Mesothelioma is an aggressive disease with limited therapeutic options. The growth factor progranulin plays a critical role in several cancer models, where it regulates tumor initiation and progression. Recent...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:333 -
LncRNA ELF3-AS1 inhibits gastric cancer by forming a negative feedback loop with SNAI2 and regulates ELF3 mRNA stability via interacting with ILF2/ILF3 complex
The biological function of lncRNA ELF3-AS1 remains largely unknown in cancers. The cause of SNAI2 overexpression in tumor metastasis remains largely unclear. The molecular mechanisms underlying the high co-exp...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:332 -
Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition
Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant tumor characterized by an intensive desmoplastic reaction due to the exaggerated presence of the extracellular (ECM) matrix components. Liver fibrob...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:331 -
UBR7 inhibits HCC tumorigenesis by targeting Keap1/Nrf2/Bach1/HK2 and glycolysis
Glycolysis metabolism is an attractive target for cancer therapy. Reprogramming metabolic pathways could improve the ability of metabolic inhibitors to suppress cancers with limited treatment options. The ubiq...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:330 -
Aerobic glycolysis enhances HBx-initiated hepatocellular carcinogenesis via NF-κBp65/HK2 signalling
Aerobic glycolysis has been recognized as one of the growth-promoting metabolic alterations of cancer cells. Emerging evidence indicates that nuclear factor κB (NF-κB) plays significant roles in metabolic adap...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:329 -
OTUD4-mediated GSDME deubiquitination enhances radiosensitivity in nasopharyngeal carcinoma by inducing pyroptosis
Radioresistance is the primary cause of nasopharyngeal carcinoma (NPC) treatment failure. Previous studies have focused on the deficits in cellular apoptosis as a mechanism for radioresistance; however, additi...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:328 -
Microglia and metastases to the central nervous system: victim, ravager, or something else?
Central nervous system (CNS) metastases are a major cause of death in patients with cancer. Tumor cells must survive during their migration and dissemination in various sites and niches. The brain is considere...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:327 -
Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma
Poor infiltration of functioning T cells renders tumors unresponsive to checkpoint-blocking immunotherapies. Here, we identified a combinatorial in situ immunomodulation strategy based on the administration of...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:326 -
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy
Improvement of efficacy of immune checkpoint blockade (ICB) remains a major clinical goal. Association of ICB with immunomodulatory epigenetic drugs is an option. However, epigenetic inhibitors show a heteroge...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:325 -
EGFR-dependent aerotaxis is a common trait of breast tumour cells
Aerotaxis, the chemotactism to oxygen, is well documented in prokaryotes. We previously reported for the first time that non-tumorigenic breast epithelial cells also display unequivocal directional migration t...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:324 -
ARPC1B promotes mesenchymal phenotype maintenance and radiotherapy resistance by blocking TRIM21-mediated degradation of IFI16 and HuR in glioma stem cells
Intratumoral heterogeneity is the primary challenge in the treatment of glioblastoma (GBM). The presence of glioma stem cells (GSCs) and their conversion between different molecular phenotypes contribute to th...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:323 -
AQP5 complements LGR5 to determine the fates of gastric cancer stem cells through regulating ULK1 ubiquitination
Cancer stem cells (CSCs) are regarded as the "seed cells" for tumorigenesis, metastasis, recurrence and drug resistance. However, specific surface markers of CSCs of different origins have not been documented.
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:322 -
A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
Medulloblastoma (MB) patients with MYC oncogene amplification or overexpression exhibit extremely poor clinical outcomes and respond poorly to current therapies. Epigenetic deregulation is very common in MYC-d...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:321 -
Correction: CircLRFN5 inhibits the progression of glioblastoma via PRRX2/GCH1 mediated ferroptosis
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:320 -
The importance of being CAFs (in cancer resistance to targeted therapies)
In the last two decades, clinical oncology has been revolutionized by the advent of targeted drugs. However, the efficacy of these therapies is significantly limited by primary and acquired resistance, that re...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:319 -
Targeting hypoxia in solid and haematological malignancies
Tumour hypoxia is a known and extensively researched phenomenon that occurs in both solid and haematological malignancies. As cancer cells proliferate, demand for oxygen can outstrip supply reducing tumour oxy...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:318 -
Retraction Note: Long non-coding RNA AGAP2-AS1, functioning as a competitive endogenous RNA, upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma
This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13046-019-1188-x.
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:317 -
Osteoblasts and osteoclasts: an important switch of tumour cell dormancy during bone metastasis
Bone metastasis occurs when tumour cells dissociate from primary tumours, enter the circulation (circulating tumour cells, CTCs), and colonize sites in bone (disseminated tumour cells, DTCs). The bone marrow s...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:316 -
LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer
Tumor-initiating cells (TIC), also known as cancer stem cells, are considered a specific subpopulation of cells necessary for cancer initiation and metastasis; however, the mechanisms by which they acquire met...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:315 -
B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met/AKT/mTOR/IRF-1 axis in neuroblastoma
Beta-1,3-galactosyltransferase-4 (B3GALT4) plays a critical regulatory role in tumor biology. However, the role of B3GALT4 in modulating the tumor microenvironment (TME) of neuroblastoma (NB) remains unknown.
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:314 -
Correction: AADAC protects colorectal cancer liver colonization from ferroptosis through SLC7A11‑dependent inhibition of lipid peroxidation
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:313 -
Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system
Cancer-associated fibroblasts (CAFs) are considered to play a fundamental role in pancreatic ductal adenocarcinoma (PDAC) progression and chemoresistance. Patient-derived organoids have demonstrated great pote...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:312 -
Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma
Medulloblastoma is the most common malignant pediatric brain tumor and group 3 subtype medulloblastoma (G3-MB) exhibits the worst prognosis. Super enhancers (SEs) are large clusters of enhancers that play impo...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:311 -
HER3 in cancer: from the bench to the bedside
The HER3 protein, that belongs to the ErbB/HER receptor tyrosine kinase (RTK) family, is expressed in several types of tumors. That fact, together with the role of HER3 in promoting cell proliferation, implica...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:310 -
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy
Aberrant activation of the MET receptor in cancer is sustained by genetic alterations or, more frequently, by transcriptional upregulations. A fraction of MET-amplified or mutated tumors are sensible to MET ta...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:309 -
Retraction Note: LncMAPK6 drives MAPK6 expressionand liver TIC self-renewal
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:308 -
CircLRFN5 inhibits the progression of glioblastoma via PRRX2/GCH1 mediated ferroptosis
Ferroptosis is a novel form of iron-dependent cell death and participates in the malignant progression of glioblastoma (GBM). Although circular RNAs (circRNAs) are found to play key roles in ferroptosis via se...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:307 -
Correction: Lycorine hydrochloride inhibits cell proliferation and induces apoptosis through promoting FBXW7-MCL1 axis in gastric cancer
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:306 -
Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer
Molecular tumor boards (MTBs) match molecular alterations with targeted anticancer drugs upon failure of the available therapeutic options. Special and local needs are most likely to emerge through the compara...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:305 -
Correction: Pim-1 acts as an oncogene in human salivary gland adenoid cystic carcinoma
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:304 -
PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the ninth member of the proprotein convertase family that regulates lipoprotein homeostasis and altered PCSK9 expression was reportedly associated with ...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:303 -
Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist
Adenosine is a potent immunosuppressant whose levels in the tumor microenvironment (TME) are often much higher than those in normal tissues. Binding of adenosine to its receptor A2aR activates a cascade of gen...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:302 -
FOXD1-dependent RalA-ANXA2-Src complex promotes CTC formation in breast cancer
Early metastasis is a key factor contributing to poor breast cancer (BC) prognosis. Circulating tumor cells (CTCs) are regarded as the precursor cells of metastasis, which are ultimately responsible for the ma...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:301 -
Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial
Neoadjuvant programmed death receptor-1 (PD-1) inhibitors have drawn increasing attention in locally advanced head and neck squamous cell carcinoma (HNSCC). In this study, we investigated the safety and effica...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:300 -
Immunotheranostic microbubbles (iMBs) - a modular platform for dendritic cell vaccine delivery applied to breast cancer immunotherapy
Therapeutic strategies engaging the immune system against malignant cells have revolutionized the field of oncology. Proficiency of dendritic cells (DCs) for antigen presentation and immune response has spurre...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:299 -
The world’s first digital cell twin in cancer electrophysiology: a digital revolution in cancer research?
The introduction of functional in-silico models, in addition to in-vivo tumor models, opens up new and unlimited possibilities in cancer research and drug development. The world's first digital twin of the A54...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:298 -
STAT3/miR-130b-3p/MBNL1 feedback loop regulated by mTORC1 signaling promotes angiogenesis and tumor growth
Aberrantly activated mammalian target of rapamycin complex 1 (mTORC1) plays a vital role in tumor angiogenesis, but its precise mechanisms are still unclear.
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:297 -
Gastric cancer-derived exosomal miR-519a-3p promotes liver metastasis by inducing intrahepatic M2-like macrophage-mediated angiogenesis
Liver metastasis (LM) is a major obstacle to the prognosis of gastric cancer (GC) patients, but the molecular mechanism underlying gastric cancer liver metastasis (GC-LM) remains unknown. Exosomes have been id...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:296 -
Exosomal circZNF451 restrains anti-PD1 treatment in lung adenocarcinoma via polarizing macrophages by complexing with TRIM56 and FXR1
Although success was achieved in the therapy for a minority of advanced lung adenocarcinoma (LUAD) patients, anti-programmed death 1 (PD1) resistance was found in most LUAD patients. Here, we aimed to uncover ...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:295 -
Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis
The family of ten-eleven translocation dioxygenases (TETs) consists of TET1, TET2, and TET3. Although all TETs are expressed in hematopoietic tissues, only TET2 is commonly found to be mutated in age-related clon...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:294 -
Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer
Protein arginine methyltransferases (PRMTs) regulate protein biological activity by modulating arginine methylation in cancer and are increasingly recognized as potential drug targets. Inhibitors targeting PRM...
Citation: Journal of Experimental & Clinical Cancer Research 2022 41:293
-
-
-
Official journal of the Regina Elena National Cancer Institute, Scientific Director Gennaro Ciliberto, Rome, Italy
-
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Sign up for article alerts and news from this journal
Annual Journal Metrics
-
2022 Citation Impact
11.3 - 2-year Impact Factor
11.5 - 5-year Impact Factor
1.870 - SNIP (Source Normalized Impact per Paper)
2.413 - SJR (SCImago Journal Rank)2023 Speed
4 days submission to first editorial decision for all manuscripts (Median)
100 days submission to accept (Median)2023 Usage
3,003,080 downloads
3,022 Altmetric mentions